Furthermore, a lipocalin (ADP355) -based peptide is also capable of inhibiting TGF-β1-induced fibrosis in keloids and can potentially treat keloids through modulation of signaling pathways such as AMPK, SMAD3, and ERK. This evidence concerns the gene TGFB1 and keloid.